Physician profile
Mitchell Mock
NPI 1346694585
$2,058.59
in general payments reported to CMS, 2019-2025
16 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.21 · 2022: $173 · 2023: $803 · 2024: $623 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,807 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.80 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $368.66 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Inari Medical, INC. | $352.84 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Lilly USA, LLC | $330.35 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $329.79 | 2022-2025 | Farxiga, Brilinta, Airsupra |
| Medtronic, INC. | $164.02 | 2023 | Endurant Iis |
| Hologic Sales and Service, LLC | $150.00 | 2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Novo Nordisk INC | $138.66 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $53.20 | 2023-2024 | |
| Amgen INC. | $27.03 | 2023 | Prolia, Evenity |
| Tanabe Pharma America, INC. | $26.76 | 2021 | |
| Amarin Pharma, INC. | $23.95 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.04 | 2023 | Jardiance, Synjardy, Tradjenta |
| Acorda Therapeutics, INC | $22.27 | 2021 | |
| Abbvie INC. | $18.18 | 2021 | |
| Pfizer INC. | $16.77 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13.07 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Mock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.